The U.S. Food and Drug Administration has accepted Novo Nordisk's marketing application for an oral version of its ...

The World Health Organization plans to officially back the use of weight-loss drugs to treat obesity in adults for the first ...

Britain's blue-chip index notched its 15th consecutive session of gains - its longest winning streak on record - as investors ...

The top sustainable finance executive at HSBC's asset management division is leaving the firm, HSBC said on Friday, the ...

A federal judge on Friday said she will allow expert testimony that formula made by Abbott Laboratories and Reckitt Benckiser ...

Euroclear plans to seize and redistribute about 3 billion euros ($3.4 billion) of Russia's funds that are frozen at the ...

Adding to the pressure is that CVS Health has retained coverage of Zepbound's arch rival Wegovy (semaglutide), sold by Novo ...

In 2023, experts decided against adding obesity drugs to the World Health Organisation's essential medicines list.

In an internal memo, the World Health Organization signaled its support for anti-obesity drugs like Wegovy and Zepbound, ...

Viking is developing what might be a game-changing medication in the segment.

The active ingredient in the popular weight loss drug Wegovy may help treat a type of fatty liver disease, according to a new study published Wednesday.

The Food and Drug Administration accepted Novo Nordisk’s marketing application for an oral version of its weight-loss drug Wegovy and will decide in the fourth quarter, the Danis ...